Renal Cancer

  • Sutent 2016 report

    Sutent 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Torisel 2016 report

    Torisel 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 22 Pages The 5 Key Questions Addressed by this Report:...

  • Votrient 2016 report

    Votrient 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Afinitor 2015 report

    Afinitor 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Avastin 2015 report

    Avastin 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 26 Pages The 5 Key Questions Addressed by this...

  • Inlyta 2015 report

    Inlyta 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 22 Pages The 5 Key Questions Addressed by this...

  • Nexavar 2015 report

    Nexavar 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Opdivo 2015 report

    Opdivo 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 28 Pages The 5 Key Questions Addressed by this...

  • Proleukin 2015 report

    Proleukin 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 26 Pages The 5 Key Questions Addressed by this...

  • Sutent 2015 report

    Sutent 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 22 Pages The 5 Key Questions Addressed by this...

  • Torisel 2015 report

    Torisel 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 22 Pages The 5 Key Questions Addressed by this...

  • Votrient 2015 report

    Votrient 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 25 Pages The 5 Key Questions Addressed by this...